NASDAQ · PLYX
Polaryx Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PLYX: Nov 12, 2026
Polaryx Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.06 | $-0.06 | $-0.06 | 2 |
| Dec 2026 | $-0.06 | $-0.06 | $-0.07 | 2 |
| Mar 2027 | $-0.08 | $-0.07 | $-0.08 | 2 |
| Jun 2027 | $-0.08 | $-0.07 | $-0.08 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews- RTTNews · Sep 1, 12:03 PM EDTPolaryx Appoints Charlton As CMO; PLX-200 Set For Phase 2 In Q4 '26(RTTNews) – Polaryx Therapeutics Inc. (PLYX), a clinical-stage biotechnology company, on Tuesday reported the appointment of Dr. Will Charlton as Chief Medical Officer (CMO), effective from September 1, 2026.
- RTTNews · Aug 25, 11:14 AM EDTPolaryx Remains On Track To Launch SOTERIA Phase 2 Basket Trial In Q4 2026; Stock Up(RTTNews) – Polaryx Therapeutics, Inc. (PLYX), a clinical-stage biotechnology company developing therapies for rare pediatric lysosomal storage disorders (LSDs), on Tuesday provided an operational readiness update for SOTERIA, its phase 2 basket trial evaluating lead candidate PL
- RTTNews · May 29, 2:27 AM EDTTop Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest(RTTNews) – In Thursday's list of gainers, we highlight SciSparc, which received the regulatory go-ahead to acquire a stake in a private Israeli technology company, Co-Diagnostics, which extended its rally for the third straight day, and Tevogen, which is making continued progres
- RTTNews · May 21, 10:34 PM EDTBiotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalysts(RTTNews) – Today's gainers include CODX, which rallied for the third straight day; Akari, on breakthrough clinical data in pancreatic cancer; Sunshine, following regulatory approval for its generic Amoxicillin; GOVX, amid Ebola concerns; and RGNX, on upcoming clinical trial mile
- RTTNews · May 15, 7:01 AM EDTPolaryx Earns Dual Honors For Its Work In Rare Pediatric Diseases; Stock Up(RTTNews) – Polaryx Therapeutics (PLYX) a clinical-stage biotech company focused on rare pediatric lysosomal storage disorders, was named Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award-USA for 2026.
- RTTNews · Apr 21, 9:02 AM EDTPolaryx Shares Rise As FDA Grants Fast-track Status Across All SOTERIA Trial Indications(RTTNews) – Shares of Polaryx Therapeutics, Inc. (PLYX) were up 10% after the company announced that the U.S. FDA has granted Fast Track Designation for all four indications to be evaluated in its upcoming SOTERIA Phase 2 basket trial.
- RTTNews · Feb 17, 10:33 AM ESTPolaryx To Initiate SOTERIA Phase 2 Basket Trial In 1H2026; Stock Up(RTTNews) – Polaryx Therapeutics, Inc. (PLYX) announced that it has selected a leading contract research organization to support SOTERIA, its Phase 2, open-label, single-arm basket trial evaluating PLX-200 in four lysosomal storage disorders (LSDs).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Polaryx Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.